Key Drivers
- Liquid balance sheet
- Persistent cash burn
- Weak asset turns
AIAI Summary
OPK is best viewed now as a balance-sheet-supported turnaround, not a pure biotech optionality play: its cash cushion and buybacks can buy time, but the stock only becomes investable if management converts modest commercial/pipeline progress into sustained positive free cash flow before ongoing losses erode liquidity.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Liquid balance sheet
- •Persistent cash burn
- •Weak asset turns
OPK has a solid, liquid balance sheet and trades below book value, but persistent losses, negative free cash flow, and weak asset productivity keep the investment case challenged.
Price Behavior
Key Price Behavior Insights:
- •Support Holding
- •Range Tightening
- •Resistance Overhead
OPK remains in a weak downtrend but is stabilizing in a tight $1.10-$1.14 range, with $1.10-$1.11 holding as support and $1.20-$1.23 now acting as resistance.
Selling pressure eased as price clustered around $1.10-$1.14 after the decline slowed
Sentiment & News
Key News Insights:
- •Revenue Decline
- •RAYALDEE Expansion
- •Pipeline Advancement
OPKO is offsetting revenue pressure from a shrinking diagnostics base by expanding RAYALDEE commercialization, launching digital testing, and advancing its biotech pipeline.
The news is modestly supportive overall, as OPKO's growth initiatives and partnerships may help counter near-term diagnostics softness, but execution risk remains high
Similar Companies in Healthcare
Other companies in the same sector with AI ratings